# A disease modifying osteoarthritis drug hasn't solved joint soreness *Regenerative Medicine Glendale | Joint Drugs in Research* > Regenerative medicine Glendale guidance on disease modifying osteoarthritis drug research and what it means for soreness. Glendale's stadium stairs can make a quiet knee announce itself, especially when the joint was already stiff or you sat through traffic on the way there. A disease modifying osteoarthritis drug is meant to slow joint changes, not just ease the ache. That sounds useful, but the drugs studied so far haven't done both jobs well. Some changed a cartilage reading while soreness stayed much the same. Others didn't do better than the comparison treatment. None has become an ordinary answer for a worn joint. Your daily ache isn't just a number. ## A better scan doesn't always mean an easier day Cartilage forms a smooth coat over each bone end in the joint. Research can measure its thickness, but that number can't tell you how stairs or sleep feel. Soreness may ease when an image doesn't change, while an image can change although the person feels no better, and that's why one result isn't enough. You'd want less aching and more useful motion before calling a joint drug helpful. For now, home care and an honest exam remain more practical than waiting on a research drug. Feeling better is the part you live with. ## If the soreness doesn't settle, ask about choices available now Write down when the joint hurts, what brings it on, and what you've already tried. Bring the X-ray report if you have one, along with your medicine names. QC Kinetix can discuss regenerative treatments, which use your blood or another body material in clinic care. The licensed medical team examines the sore joint and explains the choices that are actually offered. They won't promise that a research drug or treatment will rebuild cartilage. Ask what may improve daily use, what it costs, and how long a fair trial would take. A plain answer can keep you from paying for hope alone. ## Sources 1. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 2. OA-11, a 56-week phase 3 double-blind placebo-controlled trial, randomized 513 knee OA patients (KL 2-3) to a single intra-articular injection of the Wnt-pathway modulator lorecivivint or vehicle placebo. Lorecivivint MISSED its primary endpoint: 12-week pain NRS change was -2.24 with drug versus -2.49 with placebo (p=0.185), no other endpoint showed a discernible treatment effect, and neither group lost meaningful medial joint space over 52 weeks. Even a purpose-built, well-funded disease-modifying candidate has not beaten a placebo injection. Yazici Y, et al. — [A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/39808286/). *Clinical and experimental rheumatology*, 2025. DOI: 10.55563/clinexprheumatol/hjt118. 3. The phase II trial of lorecivivint (SM04690), an intra-articular CLK2/DYRK1A inhibitor and Wnt-pathway modulator, is the reference for how a genuine disease-modifying osteoarthritis DRUG is developed - defined molecule, defined target, dose-ranging, radiographic endpoints - which is the standard against which an unstandardised autologous injectate should be read. Yazici Y, et al. — [Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.](https://pubmed.ncbi.nlm.nih.gov/32432388/). *Arthritis & rheumatology (Hoboken, N.J.)*, 2020. DOI: 10.1002/art.41315. 4. A systematic review of the discordance between clinical and radiographic knee osteoarthritis: many people with severe-looking x-rays have little pain, and many with disabling pain have modest radiographic change. This is the reason a post-treatment scan is a poor proxy for how someone feels, in either direction. Bedson J, et al. — [The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature.](https://pubmed.ncbi.nlm.nih.gov/18764949/). *BMC musculoskeletal disorders*, 2008. DOI: 10.1186/1471-2474-9-116. ## An exam can help when soreness stays Tell the licensed clinic staff where it hurts, when it began, and what you've tried. Bring your medicine names and any old joint reports. Book a free consultation: --- Straight help for a sore joint in Glendale. See why a joint aches, steps you can try, warning signs, and regenerative choices near Glendale. Clear guidance on aching joints, simple care, warning signs, and nearby visits for Glendale readers. This Glendale evidence desk is operated by the same owners who run the QC Kinetix Phoenix-area clinics it recommends. © 2026 Glendale Regen Monitor. Educational information only; individual decisions require medical assessment.